https://www.selleckchem.com/pr....oducts/obeticholic-a
The COVID-19 pandemic is causing declines in childhood immunization rates. We examined potential COVID-19-related changes in pediatric 13-valent pneumococcal conjugate vaccine (PCV13) use, subsequent impact on childhood and adult pneumococcal disease rates, and how those changes might affect the favorability of PCV13 use in non-immunocompromised adults aged ≥65years. A Markov model estimated pediatric disease resulting from decreased PCV13 use in children aged 5years; absolute decreases from 10 to 50% for 1-2years duration
Like
Comment
Share
